Skip to main content
. Author manuscript; available in PMC: 2016 Jul 7.
Published in final edited form as: Nature. 2016 Jan 13;529(7586):351–357. doi: 10.1038/nature16478

Figure 5. Signalling pathways in recurrent medulloblastoma.

Figure 5

a, Compartment-specific deleterious events in the TP53 gene (n = 6/23), genes from the TP53 pathway (n = 12/23), DYNC1H1 (n = 3/23), and chr14q loss (3/18). Asterisk indicates mutations in patients with missing diagnostic samples; ‘d’ indicates different events in pre- and post-therapy samples; white, patients with diagnostic, post-therapy, and germline samples; grey, no germline; pink, no matched diagnostic sample; blue, Wnt; red, Shh; yellow, Group 3; green, Group 4. b, Overall survival decreases in Shh patients with a chr14q-loss gene expression signature (versus balanced, log-rank test, n = 578, P = 0.0109); not significant in non-Shh tumours. c, Prognostic differences are replicated in an independent cohort (log-rank test, n = 35, P = 0.000995).